Navigation Links
Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results
Date:3/23/2009

ifying and securing a primary care marketing partner."

The financial information provided in this press release is for Transcept Pharmaceuticals, Inc., the private corporation that merged with Novacea, Inc. and whose business is substantially the business of the combined public company. The financial results of Transcept for quarter and year ended December 31, 2008 will be filed with the Securities and Exchange Commission (SEC) on Form 8-K on or before March 31, 2009. Financial results of Novacea, Inc. for the quarter and year ended December 31, 2008 will be filed separately on Form 10-K with the SEC.

Full Year 2008 Financial Results

Research and development expenses for the year ended December 31, 2008 were $10.4 million, compared to $15.9 million for 2007. Of this $5.5 million decrease, $4.9 million is attributable to decreased expenses incurred in 2008 as the Phase 3 clinical development program for Intermezzo(R) was substantially completed in 2007. The remaining $0.6 million decrease is attributable to the reduction in expenditures for the Company's earlier stage development programs. Research and development expenses included non-cash stock compensation expense in accordance with Statement of Financial Accounting Standards, or SFAS, No. 123R of $0.3 million for the year ended December 31, 2008 and $0.2 million for the year ended December 31, 2007.

General and administrative expenses for 2008 were $7.9 million, compared to $5.3 million for 2007. Of this $2.6 million increase, approximately $1.7 million is attributable to higher professional fees incurred in preparation for operating as a publicly traded company, and increased headcount and related salary expenses. The remaining $0.9 million is attributable to market research expenses to support the development of the Intermezzo(R) commercialization plan. General and administrative expenses included non-cash stock compensa
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
2. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
3. Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.
4. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
5. Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
6. Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
7. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
8. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
9. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
10. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
11. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 01, 2015 On May 14, ... center hosted the Cherry Creek Chamber of Commerce ... clinic. Urgent care centers typically do not offer primary ... AFC/Doctors Express Cherry Creek Urgent Care staff to schedule ... , From 5:30 to 7:30 p.m. the center hosted ...
(Date:6/1/2015)... "This milestone opens the doors to institutional ... to buy and sell shares of our Company. ... make recommendations to clients as they so choose. It ... shares of our Company,” said Kris Finstad, Content Checked’s ... OTCQB provides our investors greater confidence in the information ...
(Date:6/1/2015)... York, NY (PRWEB) June 01, 2015 ... by patients requesting celebrity features. Much like one would ... favorite stars’ noses, eyes, cheeks, chin and more to ... photo filtering apps like FaceTune are ushering in a ... Top Manhattan facial plastic surgeon, Sam Rizk, MD, FACS ...
(Date:6/1/2015)... June 1, 2015 – Atlanta, GA ... the areas of hospital medicine, emergency medicine, and pediatric ... expanded upon its partnership with AgileMD to provide the ... in a mobile application format available on iPhones, ... are very excited about the June 1 launch of ...
(Date:6/1/2015)... InstantLabs will co-develop and commercialize a ... a Cooperative Research and Development Agreement (CRADA) with the ... with U.S. Farm Bill legislation, only members of the ... the United States. , InstantLabs’ DNA-based technology will ... need rather than requiring samples be sent to centralized ...
Breaking Medicine News(10 mins):Health News:Grand Opening For AFC/Doctors Express Cherry Creek Primary Care Clinic 2Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 2Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 3Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 4Health News:Instagram Filters Launch New Facial Plastic Surgery Trend 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 3Health News:InstantLabs Partners with FDA to Commercialize Catfish Species Identification Test 2Health News:InstantLabs Partners with FDA to Commercialize Catfish Species Identification Test 3Health News:InstantLabs Partners with FDA to Commercialize Catfish Species Identification Test 4
... Human papillomavirus infection linked to better prognosis, research suggests ... the human papillomavirus (HPV) may improve survival in patients ... They said the finding may explain why black Americans, ... poorer head and neck cancer survival rates. , "There ...
... , , Association,s Anti-Fraud ... Fraud, and Abuse in Medicare , , ... strongly supports the recent Medicare Fraud Strike Force crackdown on Medicare ... takes vital resources away from seniors and patients. Reducing fraud and ...
... , YOUNTVILLE, Calif., July 30 The following is being ... WHAT: A special hearing of the California Senate Veterans Affairs Committee at the ... was originally , scheduled for Friday, July 31, 2009 at 9 a.m.. , ... , ...
... , , DETROIT, July 30 ... Rev. Dr. Wendell Anthony: , , Congressman Thaddeus ... to apologize for his remarks to the Cambridge Police Department. ... he should start by issuing an apology to the citizens of ...
... PASADENA, Calif., July 30 AutoImmune Inc. (OTC ... Corp., and Eli Lilly and Company reported that dirucotide ... progression, as measured by the Expanded Disability Status Scale ... with secondary progressive multiple sclerosis (SPMS). In addition, there ...
... PLEASANTON, Calif., July 30 Thoratec Corporation (Nasdaq: THOR ... save, support and restore failing hearts, today announced that it will ... months of fiscal 2009 on Wednesday, August 5. , , ... its financial results and operating activities open to all interested parties ...
Cached Medicine News:Health News:Virus May Affect Survival in Head and Neck Cancer 2Health News:American Association for Homecare Supports Crackdown on Medicare Scammers in Houston, Boston, New York, Louisiana 2Health News:American Association for Homecare Supports Crackdown on Medicare Scammers in Houston, Boston, New York, Louisiana 3Health News:American Association for Homecare Supports Crackdown on Medicare Scammers in Houston, Boston, New York, Louisiana 4Health News:Clinical Trial by Licensee Does Not Meet Primary Endpoint 2Health News:Thoratec Schedules Second Quarter Conference Call, Webcast 2
(Date:6/1/2015)... -- Boston Biomedical, an industry leader in the development of ... pathways, will present clinical data today on the investigational ... the 2015 American Society of Clinical Oncology (ASCO) annual ... Data presented at ASCO highlight the potential of BBI608 ... to inhibition of the critical genes for maintaining cancer ...
(Date:6/1/2015)... /CNW Telbec/ -  Ergoresearch Ltd (TSXV: ERG) – based ... « Équilibre, orthèses et biomécanique» banner  – announces its ... All dollar amounts in the present release are in Canadian ... fiscal year 2015 ended this past March 31, 2015 totaled ... for the quarter ended March 31, 2014. This decrease can ...
(Date:6/1/2015)... 1, 2015 /PRNewswire/ - Merus Labs International Inc. ("Merus" ... ) is pleased to announce today that the ... the over-allotment option to purchase 1,000,550 common shares ... C$3.05 per Share granted to the Underwriters in ... which closed on April 30, 2015.  The Company ...
Breaking Medicine Technology:Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 2Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 3Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 4Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 5Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 6Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 7Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 2Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 3Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 4Merus Labs International Inc. Announces Closing of Exercise of Over-Allotment Option 2
... 2011 S*BIO Pte Ltd today announced that its ... (PK/PD) properties leading to significant anti-tumor efficacy in rapamycin-sensitive ... in vitro data on SB2343 were presented ... on Targeting PI3K/mTOR Signaling in Cancer held in San ...
... Feb. 28, 2011 PDL BioPharma, Inc. (PDL) (Nasdaq: ... Appeal of the European Patent Office (EPO) has cancelled its ... decision upholding PDL,s  European Patent No. 0 451 216B (the ... the termination of the opposition appeal proceeding is that the ...
Cached Medicine Technology:S*BIO's Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models 2S*BIO's Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models 3PDL BioPharma Announces European Patent Office Determination of Validity of PDL's European Patent is Final 2
Inquire...
... System consists of a sterile Hemostatic ... Compression System.,Both devices work together to ... achieves topical hemostasis by facilitating clotting ... Femoral Compression System provides external compression ...
... PRAXIS is an Electronic Medical Record system. ... EKG's, Vital Statistics, Medications, and everything you would ... charts cost you money. Someone has to write ... them, and organize them. Paper Charts get lost. ...
... Bausch & Lomb's Orbscan IIz is ... elevates diagnostics beyond mere topography. Unlike current ... the eye at standard points, the Orbscan ... 1.5 seconds to meticulously map the entire ...
Medicine Products: